Table 1.
Demographic and clinicopathologic features of patients between the control cohort and PMRT cohort in T-2 breast cancer with 1-3 positive lymph nodes.
| Characteristic | Control cohort (11917) | PMRT cohort (6690) | P |
|---|---|---|---|
| Marital status | 0.209 | ||
| Married | 7761(65.1) | 4418(66.0) | |
| USDW | 4156(34.9) | 2272(34.0) | |
| Age (years) | <0.001 | ||
| 20-39 | 1223(10.3) | 1093(16.3) | |
| 40-49 | 3465(29.1) | 2240(33.5) | |
| 50-59 | 3908(32.8) | 1970(29.4) | |
| 60-69 | 3321(27.9) | 1387(20.7) | |
| Race | <0.001 | ||
| White | 9333(78.3) | 5080(75.9) | |
| Black | 1291(10.8) | 845(12.6) | |
| Other | 1293(10.9) | 765(11.4) | |
| Histology | 0.967 | ||
| Infiltrating duct cancer | 10871(91.2) | 6104(91.2) | |
| Infiltrating lobular carcinoma | 1046(8.8) | 586(8.8) | |
| Grade | <0.001 | ||
| 1 | 1578(13.2) | 582(8.7) | |
| 2 | 5172(43.4) | 2786(41.6) | |
| 3 | 5167(43.4) | 3322(49.7) | |
| Laterality | 0.728 | ||
| Left | 6024(50.5) | 3364(50.3) | |
| Right | 5893(49.5) | 3326(49.7) | |
| T stage | <0.001 | ||
| T1 | 5346(44.9) | 2222(33.2) | |
| T2 | 6571(55.1) | 4468(66.8) | |
| Chemotherapy | <0.001 | ||
| No | 3259(27.3) | 456(6.8) | |
| Yes | 8658(72.7) | 6234(93.2) | |
| ALND | <0.001 | ||
| No | 4289(36.0) | 2074(31.0) | |
| Yes | 7628(64.0) | 4616(69.0) | |
| Examined lymph nodes | 0.001 | ||
| Median (IQR) | 12(8-17) | 12(7-17) | |
| Positive lymph nodes | <0.001 | ||
| 1 | 6701(56.2) | 2815(42.1) | |
| 2 | 3562(29.9) | 2198(32.9) | |
| 3 | 1654(13.9) | 1677(25.1) | |
| ER | <0.001 | ||
| Negative | 2350(19.7) | 1490(22.3) | |
| Positive | 9567(80.3) | 5200(77.7) | |
| PR | <0.001 | ||
| Negative | 3526(29.6) | 2175(32.5) | |
| Positive | 8391(70.4) | 4515(67.5) |
USDW, unmarried/separated/divorced/widowed; Other, American Indian/AK Native, Asian/Pacific Islander; grade 1, well differentiated; grade 2, moderately differentiated; grade 3, poorly differentiated/undifferentiated; ALND, axillary lymph node dissection; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.